Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kairos Pharma (KAPA) Common Equity (2024 - 2025)

Kairos Pharma (KAPA) has disclosed Common Equity for 2 consecutive years, with $6.0 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Common Equity rose 325.96% year-over-year to $6.0 million, compared with a TTM value of $6.0 million through Jun 2025, up 325.96%, and an annual FY2024 reading of $4.8 million, changed N/A over the prior year.
  • Common Equity was $6.0 million for Q2 2025 at Kairos Pharma, down from $7.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $7.1 million in Q1 2025 and bottomed at -$2.7 million in Q2 2024.